Expert Review of Clinical Pharmacology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Challenges and considerations for treating PTSD with medicinal cannabis: the Australian clinician's perspective
Expert Rev Clin Pharmacol. 2023 Oct 27. doi: 10.1080/17512433.2023.2276309. Online ahead of print.ABSTRACTINTRODUCTION: Preclinical and experimental research have provided promising evidence that medicinal cannabis may be efficacious in the treatment of posttraumatic stress disorder (PTSD). However, implementation of medicinal cannabis into routine clinical therapies may not be straightforward.AREAS COVERED: In this review, we describe some of the clinical, practical, and safety challenges that must be addressed for cannabis-based treatment of PTSD to be feasible in a real-world setting. These issues are especially prevale...
Source: Expert Review of Clinical Pharmacology - October 27, 2023 Category: Drugs & Pharmacology Authors: Luke J Ney Wole Akosile Chris Davey Louise Pitcher Kim L Felmingham Leah M Mayo Matthew N Hill Esben Strodl Source Type: research

The expert clinical pharmacological advice program for tailoring on real-time antimicrobial therapies with emerging TDM candidates in special populations: how the ugly duckling turned into a swan
This article aims to highlight the main key-points and organizational aspects for implementing a successful TDM-based expert clinical pharmacological advice (ECPA) program for tailoring antimicrobial therapies on real-time in different hospitalized patient special populations.EXPERT OPINION: TDM-based ECPA programs lead by the MD Clinical Pharmacologist may represent a way forward for maximizing clinical efficacy and for minimizing the risk of resistance developments and/or toxicity of antimicrobials. Stakeholders should be aware of the fact that this innovative approach may be cost-effective.PMID:37874608 | DOI:10.1080/17...
Source: Expert Review of Clinical Pharmacology - October 24, 2023 Category: Drugs & Pharmacology Authors: Milo Gatti Federico Pea Source Type: research

Efficacy and safety of tislelizumab for malignant solid tumor: a systematic review and meta-analysis of phase III randomized trials
Expert Rev Clin Pharmacol. 2023 Oct 21. doi: 10.1080/17512433.2023.2274544. Online ahead of print.NO ABSTRACTPMID:37864420 | DOI:10.1080/17512433.2023.2274544 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - October 21, 2023 Category: Drugs & Pharmacology Authors: Aws Khalid Abushanab Mus'ab Theeb Mustafa Mahmoud Taysir Mousa Rana Ahmed Qawaqzeh Ghaith Nahar Alqudah Renad Fawwaz Albanawi Source Type: research

A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia
Expert Rev Clin Pharmacol. 2023 Oct 21. doi: 10.1080/17512433.2023.2274538. Online ahead of print.ABSTRACTINTRODUCTION: The challenges posed by treatment-resistant schizophrenia and depressive symptoms have led to ongoing difficulties despite the availability of antipsychotics and antidepressants. This review addresses the potential of amisulpride analogs, particularly SEP-4199, in addressing these challenges through enhanced efficacy and reduced side effects.AREAS COVERED: This review focuses on the pharmacological profile of amisulpride analogs, exemplified by LB-102 and its derivative SEP-4199. PubMed gathered articles ...
Source: Expert Review of Clinical Pharmacology - October 21, 2023 Category: Drugs & Pharmacology Authors: Jie Wu Angela Th Kwan Taeho Greg Rhee Roger Ho Giacomo d'Andrea Giovanni Martinotti Kayla M Teopiz Felicia Ceban Roger S McIntyre Source Type: research

The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease
Expert Rev Clin Pharmacol. 2023 Oct 21. doi: 10.1080/17512433.2023.2274536. Online ahead of print.ABSTRACTINTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent disease, associated with obesity, type 2 diabetes mellitus and dyslipidemia, which can lead to liver cirrhosis and hepatocellular carcinoma in some patients. Apart from lifestyle modifications, which are the cornerstone for its management, several drugs are under evaluation, including glucagon-like peptide-1 receptor agonists (GLP-R1RAs). In this review, we summarized major clinical data concerning the effects of GLP-1RAs on NAFLD, trying to h...
Source: Expert Review of Clinical Pharmacology - October 21, 2023 Category: Drugs & Pharmacology Authors: Chara Tsiampali Paraskevi Papaioannidou Antonis Goulas Stergios A Polyzos Source Type: research

The new evidence on cardiorenal benefits of sodium-glucose cotransporter 2 inhibitors in type 1 diabetes: one step closer to their use in this setting?
Expert Rev Clin Pharmacol. 2023 Oct 21. doi: 10.1080/17512433.2023.2274988. Online ahead of print.ABSTRACTChronic kidney disease (CKD) affects 30-40% of persons with type 1 diabetes mellitus (T1DM), markedly increasing the risk of kidney failure and cardiovascular events. The excessive mortality observed in T1DM compared to the general population can be attributed to the presence of CKD, with cardiovascular disease as the leading cause of premature death. A recently published, robust real-world study investigated the impact of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists ...
Source: Expert Review of Clinical Pharmacology - October 21, 2023 Category: Drugs & Pharmacology Authors: Djordje S Popovic Theocharis Koufakis Dimitrios Patoulias Nikolaos Papanas Source Type: research